Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Praneet Korrapati

Internal Medicine Raleigh, NC Medical Doctor

NPI 1467895748 CMS profile 974735

2417 Atrirum Drive, Ste 150, Raleigh, NC 27603

Open in the dashboard

General payments

$8,124

382 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Praneet Korrapati of Raleigh, NC is reported in the CMS Open Payments database as having received $8,124 across 382 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,502 69
2024 General $1,368 68
2023 General $2,253 90
2022 General $1,092 59
2021 General $790 41
2020 General $550 32
2019 General $570 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Praneet Korrapati
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Praneet Korrapati were reported at $1,502. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Praneet Korrapati Internal Medicine median Middle half National median
2019 $570 $159 $48–$570 $163
2020 $550 $119 $33–$402 $114
2021 $790 $135 $37–$521 $132
2022 $1,092 $141 $42–$496 $149
2023 $2,253 $149 $45–$519 $160
2024 $1,368 $154 $47–$537 $164
2025 $1,502 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,018 162 payments
  2. Boston Scientific Corporation $799 11 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $646 37 payments
  4. Pfizer Inc. $588 33 payments
  5. Gilead Sciences, Inc. $467 23 payments
  6. ERBE USA Inc $285 2 payments
  7. Janssen Biotech, Inc. $268 10 payments
  8. Intercept Pharmaceuticals, Inc. $247 9 payments
  9. Merck Sharp & Dohme Corporation $209 13 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $207 11 payments
  11. Other $1,387 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,997 378 payments
  2. Education $109 3 payments
  3. Gift $18 1 payment
Products named General payments · program years 2019–2025
  1. CREON $881 50 payments
  2. RINVOQ $807 49 payments
  3. SKYRIZI Immunology $771 38 payments
  4. LINZESS $753 45 payments
  5. ENTYVIO $512 30 payments
  6. XELJANZ $507 29 payments
  7. HUMIRA $376 22 payments
  8. SKYRIZI Immunology $343 17 payments
  9. Erbe APC $285 2 payments
  10. VELSIPITY $274 17 payments
  11. Other $3,857 169 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

508

Median for Gastroenterology: 569

Drug cost

$148,425

Median for Gastroenterology: $104,976

Branded share of claims

32.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 12 $78,849
Linzess Linaclotide Brand 26 $24,903
Mesalamine Generic 14 $13,353
Trulance Plecanatide Brand 13 $10,916
Colestipol Hcl Generic 57 $8,597
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 42 $2,669
Ursodiol Generic 11 $1,883
Pantoprazole Sodium Generic 138 $1,804
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 12 $1,492
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 58 $1,457

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$47,092

Medicare's payments for the services billed

Medicare patients

233

Average age 72

Services billed

750

128 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 41%
Ischemic heart disease 29%
Depression 28%
Chronic kidney disease 24%
Heart failure 20%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $308
$308 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $150
$150 — —
LINZESS
  • AbbVie, Inc. $133
$133 26 —
CREON
  • AbbVie, Inc. $117
$117 — —
RINVOQ
  • AbbVie, Inc. $109
$109 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

382 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record